Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05415137 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | PHASE3 | COMPLETED | 268 | — | — | Sep 15, 2022 | Jul 14, 2025 | Jun 4, 2026 | 91 | United States, Brazil +7 |
| Arm | Type | Description |
|---|---|---|
| Efzofitimod 3 mg/kg | EXPERIMENTAL | - |
| Efzofitimod 5 mg/kg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Efzofitimod 3 mg/kg | DRUG | Efzofitimod IV infusion every 4 weeks for a total of 12 doses |
| Efzofitimod 5 mg/kg | DRUG | Efzofitimod IV infusion every 4 weeks for a total of 12 doses |
| Placebo | DRUG | Placebo IV infusion every 4 weeks for a total of 12 doses |
Inclusion Criteria: * Documented history of pulmonary sarcoidosis for at least 6 months, supported by the following evidence: documented histologically proven diagnosis of sarcoidosis by tissue biopsy and documented evidence of parenchymal lung involvement by historical radiological evidence * Evid...